Dova Pharmaceuticals (NASDAQ:DOVA) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Thursday.
A number of other equities analysts also recently commented on DOVA. LADENBURG THALM/SH SH lifted their price objective on shares of Dova Pharmaceuticals to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 18th. They noted that the move was a valuation call. HC Wainwright initiated coverage on shares of Dova Pharmaceuticals in a report on Thursday, December 20th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, JPMorgan Chase & Co. downgraded shares of Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and decreased their price objective for the stock from $34.00 to $20.00 in a report on Wednesday, January 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $29.50.
Dova Pharmaceuticals stock opened at $8.80 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.73 and a quick ratio of 5.51. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $35.33.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.08. Equities research analysts predict that Dova Pharmaceuticals will post -2.31 EPS for the current fiscal year.
In other news, Director Paul B. Manning purchased 68,000 shares of Dova Pharmaceuticals stock in a transaction dated Thursday, March 7th. The stock was bought at an average price of $7.48 per share, with a total value of $508,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 55.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Dova Pharmaceuticals by 8.1% during the fourth quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock valued at $1,184,000 after acquiring an additional 11,732 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Dova Pharmaceuticals during the fourth quarter valued at $137,000. Two Sigma Investments LP acquired a new position in shares of Dova Pharmaceuticals during the fourth quarter valued at $136,000. Sphera Funds Management LTD. boosted its holdings in shares of Dova Pharmaceuticals by 54.2% during the fourth quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock valued at $1,402,000 after acquiring an additional 65,000 shares during the period. Finally, Broadfin Capital LLC acquired a new position in shares of Dova Pharmaceuticals during the fourth quarter valued at $2,667,000. 30.09% of the stock is owned by institutional investors.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Featured Story: What is a trade deficit?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.